Compare Amgen, Inc. (AMGN) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Nasdaq Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Nasdaq Inc trades at $87.79 (market cap $49.81B). The key difference: Amgen, Inc. is far larger — about 3.9× Nasdaq Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | NDAQ | |
|---|---|---|
Market Cap | $196.12B | $49.81B |
Sector | Health | Financials |
52-Week High | $388.16 | $100.98 |
52-Week Low | $271.18 | $76.85 |
Enterprise Value | $241.41B | $56.88B |
Dividend Yield | 2.77% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Nasdaq (NDAQ) trades at $88.08, up 0.64% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. Revenue grew to $8.26 billion in 2025, with net income margin expanding to 23.03%. The stock shows robust institutional support, with 61% of analysts rating it a Buy and a consensus price target of $105.60, indicating ~20% upside potential.
Outlook remains positive given Nasdaq's dominant market position and exposure to capital markets growth, though risks include high valuation multiples (P/E 26.53) and sensitivity to equity market volatility. The stock's recent strength near resistance at $89 may prompt consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
